NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that Centre Hospitalier Universitaire (CHU) de Limoges, in Limoges, France has installed Masimo’s Radical-7®, including noninvasive, continuous hemoglobin (SpHb®), Pleth Variability Index (PVI®), and SET® pulse oximetry technology, to monitor surgical patients and critical patients in the post-anesthesia care unit and intensive care unit.
“For three years, we tested SpHb and PVI on every surgical patient in our facility and then compared this data to the previous period without this technology,” said Professor Nathalie Nathan, Head of the Department of Anesthesiology at CHU Limoges. “In this retrospective review of before and after periods across the entire hospital, in different clinical settings and with many different practitioners, we found that there was a notable reduction in mortality in surgeries lasting longer than 2 hours and patients in the 60+ age range.”
SpHb is a breakthrough measurement that noninvasively and continuously measures total hemoglobin in the blood, and offers real-time visibility into changes – or lack of changes – in hemoglobin between invasive blood samples. PVI is a measure of dynamic changes in Perfusion Index (PI) that occur during one or more complete respiratory cycles, and may show changes that reflect physiologic factors such as vascular tone, circulating blood volume, and intrathoracic pressure excursions. PVI is noninvasive, easily obtained and has no incremental procedural cost.
“According to the World Health Organization, France ranks number one in the world in patient safety. For over 40 years, CHU Limoges has been recognized as a leading hospital in France for patient care, training, research and innovation,” stated Joe Kiani, Founder and CEO of Masimo. “We are impressed with the format of this three-year evaluation and happy to see Limoges incorporate SpHb and PVI in the care of their patients.”
CHU Limoges is a university hospital that includes four locations and one nursing home. Dupuytren (866 beds) hosts an emergency department, Jean Rebeyrol (459 beds) handles rehabilitation patients, Cluzeau (59 beds) specializes in respiratory diseases, diabetes, endocrinology and metabolic diseases, and Mother & Child (197 beds) specializes in pediatric and gynecological emergencies and has 197 beds.
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect (MOC-9) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo’s SpHb®, PVI®, and SET® technologies. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo’s SpHb®, PVI®, and SET® technologies, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
